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Abstract 
Background: Parkinson's disease (PD) is a neurodegenerative disorder impairing motor, verbal and other 
abilities. Visual evoked potential (VEP) assessment is a useful method for analysis of visual system and its 
function. The present study was designed in order to evaluate whether VEP changes are associated with PD. 
Materials and Methods: In the present study, 100 subjects encompassing 40 patients with Idiopathic 
Parkinson’s Disease (Idiopathic PD) and 60 aged-matched controls were selected and assigned into case and 
control groups, respectively. VEP analysis was conducted in either group and the results were compared. 
Results: In the present study, 16 patients (40%) showed prolonged P100 latency. P100 latency in the case 
group was significantly longer than in controls. P100 Amplitude was significantly higher in case group than 
control. There were no significant association between prolonged VEP and sex and diseases duration, in the 
participants. Also from our participants who suffer from visual hallucination, P100 latency was significantly 
longer than in the controls.  There was a significant association between prolonged P100 latency and severity 
of disease in the case group. 
Conclusion: We suggest that prolonged VEP latencies and amplitude are associated with PD and might be 
associated with a predisposition for visual hallucinations. 
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Introduction 
Parkinson's disease (PD) is one of the paramount 





 Over 4 million people with 
age above 50 years present with PD and this rate is 
assumed to double during the next 2 decades
3
. 
Although PD pathogenesis is complex nevertheless, 
genetics has been shown to be a crucial contributing 
factor
4
. Tremor is the most apparent symptom in PD; 
even so, bradykinesia, rigidity, postural instability are 
present
5
. In spite of the movement difficulties bringing 
about motor symptoms, PD patients may experience 
non-motor symptoms encompassing autonomic 
dysfunction, neuropsychiatric problems and sensory, 
sleep and visual problems
5
. It is said that 60 to 80 
percent of dopaminergic neurons are destroyed in the 
motor impairment. PD is almost incurable; but 
Levodopa, which is administered to compensate this 
imbalance, is a common treatment for PD
6
. MAO-B 
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inhibitors, dopamine antagonists and surgery have 
been used to treat PD. Modafinil has also been 
demonstrated to exert antiparkinsionian effect
7
. One 
of the manifestations of PD is impaired vision 
system. Visual hallucination (seeing things)
8
 and 
impaired determination of lines positions and 
directions
9
 are also seen in PD. Patients’ visual 
contrast is also impaired, especially in low-light 
environments. Not only are PD patients’ eyes unable 
to be kept in top position, but also they cannot focus 
on objects and follow them
10,11
. This impairment may 
be due to a reduction in dopamine level in retina, or 
dopamine’s effect upon Geniculatus lateralis nucleus 
synapsis and visual cortex
12,13
. Visual evoked 
potential (VEP) refers to a potential resulting from 
visual cortex response to visual stimuli. It is a useful 
criterion in order to evaluate visual system function 
and optic tract. VEP provides valuable information in 
patients with hemodialysis and peritoneal dialysis . In 
several studies, VEP analysis has been applied to 









. VEP is 
classified into PR-VEP (pattern reversal) using 
checkerboard stimuli and F-VEP using flash stimuli, 
but the former is more sensitive. VEP results 
incorporates N75 latency, P100 latency, N140 
latency, P100 amplitude; even so, P100 latency is the 
best wave for assessment of VEP results
9,20
. Several 
studies devoted attention to impaired visual system in 
PD patients, howbeit, little is known about the 
usefulness of VEP findings in diagnosis of PD. 
Calzetti et al. 
 
reported that prolonged VEP latencies 
were affected by PD, they can be helpful in clinical 
diagnosis of early PD
21
. Tartaglione et al. also 
showed that PD gave rise to prolonged Lat P100
22
. 
The importance of the present study lies in the fact 
that little is known about the usefulness of VEP 
findings in diagnosis of PD severity.  
The present study covers the gap created by the little 
available information regarding the association of 
VEP results with disease severity and visual 
hallucination. Therefore, our aim was to explore the 
association of VEP results with severity and visual 
problems of PD, which was not covered by the 
previous published studies. To be more precise, we 
specifically investigated VEP results in PD patients 
and controls, and assessed the association of VEP 
results with disease duration, disease severity and 
visual hallucination. 
Methods 
In the present study, a case-control design was 
utilized. Forty PD patients were recruited from 
November 2008 to April 2010. These subjects were 
selected from PD statistical population of the East 
Azarbaijan province (recruited from two different 
centers include neurology ward of Imam Reza hospital 
and Sheikhorraeis clinic, Tabriz University of Medical 
Sciences, Tabriz, Iran). Sixty controls were selected 
from various hospital wards excepting neurology and 
ophthalmologic wards to preclude selection bias. The 
controls were also controlled by a clinician for not 
presenting with neurologic or ophthalmologic 
problems.  Study size was calculated using data 
published in a preceding thesis. The case group were 
clinically selected according to diagnostic criteria for 
PD
23
. The PD subjects were being treated by Madopar, 
Amantadine, and Trihexyphenidyl; however, these 
medications would not affect the VEP finding in PD 
subjects. It is worth mentioning that PD subjects and 
controls presenting with diseases, affecting VEP 
findings such as ophthalmologic diseases, multiple 
sclerosis, history of stroke, migraine, renal failure, 
diabetic retinopathy, hypertensive retinopathy, 
glaucoma, and cataract, were excluded from the study. 
The cases were then subdivided to 7 subgroups 
predicated upon Hoehn and Yahr criteria
24
 in order to 
assess the association of VEP findings with increase in 
disease severity. The subjects were also subdivided 
into 3 subgroups (< 1 year, 1 year < < 5 years, 5 years 
<) in order to assess the association of VEP findings 
with disease duration. Although no previous study 
utilized such subdivision, this provided a novel and 
more precise assessment of the duration of PD. The 
patients with visual hallucination (seeing things) were 
clinically diagnosed by a neurologist in order to assess 
the association of VEP findings with visual 
hallucination. Sixty subjects were selected for the 
control group (1.5 controls per case). To limit 
confounding effect, a frequency matching was carried 
out for cases and controls predicated upon age 
(˃50years & <50years). The outcome included 
Idiopathic Parkinson Disease which was rated by 
means of MDS-UPDRS rating scale
25
, and the 
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exposure was VEP results. A questionnaire was 
prepared and a complete history of each patient was 
recorded. All the subjects were assessed for VEP by 
using four channeled Neuroscan plus Tonnis. By 
means of Oz-Fz electrode location, an apparatus 
sensitivity of 20, checker board pattern of apparatus 
and standard color, visual stimuli were given to 
visual field. It is worth noting that assessment of 
VEP is a non-invasive study. All participants gave an 
informed consent prior to commencement of the 
study. All the protocols of the research were 
approved by the ethical research committee of Tabriz 
University of Medical Science. Statistical analyses 
were performed using the SPSS statistical software 
package (Version 15.0). More precisely, Chi square 
was used for categorical variables and t-test analysis 
was applied for quantitative variables. The results 
were significant at the p-value<0.05 level. 
Results 
Table 1 shows demographic information of the case 
and control group. No significant difference was 
observed in gender between cases and controls.  
Disease duration was from 3 months to 20 years with 
an average of 8.2±6.45. Nine out of 40 patients 
presented with visual hallucination (22.5%). Of these 
patients, 4 cases were male (15.4%) and 5 cases were 
female (35.7%). 
Table 2 provides a breakdown pertaining to VEP results 
in the case and control groups. P100 latency in the cases 
was significantly longer than in the controls (p<0.0001). 
N140 latency in the cases was significantly longer than in 
Table 1: Demographic information of the case and 
control groups. 




Gender 26 males 36 males  






38- 76 years 
 
 





Mean ± Standard deviation P value 
Case group Control 
group 
Lat N75 81.77±9.68 78.33±5.15 0.04* 
Lat P100 114.80±16.61 110.44±4.53 0.0001* 
Lat N140 159.82±14.99 144.71±9.32 0.0001* 
Amp P100 13.51±11.56 8.93±5.20 0.002* 
Note: Lat N75: N75 latency, Lat P100: P100 latency, Lat 
N140: N140 latency, Amp P100: P100 amplitude; *P-
value<0.05 
Table 3: Association between duration of disease and VEP findings. 
VEP latency and 
amplitude 
Duration of disease (Mean ± Standard deviation) p-value 
 < 1year 1year<    <5years Less than 5years  
Lat N75 80.95±10.41 81.34±10.72 82.79±8.74 0.852 
Lat P100 108.60±26.15 114.38±17.15 118.65±8.66 0.522 
Lat N140 159.04±7.41 158.94±16.45 161.82±17.02 0.69 
Amp P100 15.99±16.11 15.29±13.45 9.72±2.96 0.505 
Note: Lat N75: N75 latency, Lat P100: P100 latency, Lat N140: N140 latency, Amp P100: P100 amplitude; *p-value<0.05 
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controls (p<0.0001). N75 latency in cases was 
significantly prolonged, in comparison with that of 
control group (p<0.04). P100 amplitude was 
significantly higher in the case group than in the control 
group (p<0.02). 
There was no significant association between P100 
latency between two eyes in cases (p=0.90). Moreover, 
24 patients (60%) experienced a normal P100 latency 
(118 ms), notwithstanding 16 patients (40%) with a 
P100 latency of longer than normal. 
There was no significant association between prolonged 
VEP findings and gender in the patients with PD. It is 
worth noting that there was a no significance 
association between prolonged P100 latency and gender 
(p=0.343). 
Table 3 indicates the association between disease 
duration and VEP findings. No significant association 
was found between prolonged VEP findings and 
disease duration in the patients with PD.  
Table 4 depicts VEP findings with hallucination. N140 
latency was significantly longer in the patients with 
hallucination than in the control group (p=0.02). 
Patients with visual hallucination showed P100 latency 
longer compared controls (p=0.05). Table 5 illustrates 
the association of VEP findings with an increase in 
disease severity. There was a significant association 
between P100 latency and the increase in disease 
severity (p=0.04). N140 latency was significantly 
associated with the increase in disease severity 
(p=0.006). 
Discussion 
Visual problem is one of the characteristics of PD and 
VEP analysis as a useful assessment of visual system 
can give assistance to neurologists to diagnose PD 
visual problems. Recently, there has been an 
increasing interest in investigating visual problems in 
PD patients; nonetheless, little is known about the 
usefulness of VEP findings in diagnosis of PD. This 
investigation, thus, sought to address the question 
whether VEP findings are associated with PD. The 
findings of the present study indicated that all VEP 
findings including Lat N75, Lat P100, Lat N140, Amp 
P100 were associated with PD. Our findings produced 
results, which corroborated the findings of Tartaglione 
et al. investigating VEP findings in 13 PD subjects and 
13 controls
22
. The authors observed that 69 percent of 
the PD subjects experienced prolonged P100 latencies.  
Another study was carried out by Calzetti et al. on 9 
patients (4 men, 5 women) and 12 controls and 
significant prolonged latencies were found in VEP 
results in the patients, compared to the controls
21
. 
Kurita et al. demonstrated visual hallucination in PD 
patients
26
. We found that hallucination influenced Lat 
P100 and Lat N140 in patients with PD. In this regard, 
our findings were consistent with those of Matsui et al. 
who studied VEP results in PD patients with 
hallucination and observed an association between 
visual hallucination and prolonged P100 latency
27
. Be 
that as it may, Onofrj et al. reported that abnormal 





Mean±Standard deviation p- 




Lat N75 83.77±12.30 78.33±5.15 0.49 
Lat P100 124.22±15.01 110.44±4.53 0.05* 
Lat N140 169.56±19.85 144.71±9.32 0.02* 
Amp P100 11.17±4.72 8.93±5.20 0.5 
Note: Lat N75: N75 latency, Lat P100: P100 latency, Lat 
N140: N140 latency, Amp P100: P100 amplitude; *p-
value<0.05 
 
Table 5: Association of VEP findings with increase 




Lat N75 0.978 
Lat P100 0.04* 
Lat N140 0.006* 
Amp P100 0.34 
Note: Lat N75: N75 latency, Lat P100: P100 latency, Lat 
N140: N140 latency, Amp P100: P100 amplitude; *p-
value<0.05 
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VEP results did not correlate with the incidence of 
hallucination in patients with PD
28
. According to our 
results, no relationship was observed between VEP 
findings and duration of disease. We also found that 
prolonged P100 and N140 latencies were associated 
with increase in severity of disease. This result 
support the findings of Kupersmith et al., reporting a 
positive association of P100 latency with the severity 
of the movement disability
29
. The evidence from the 
present study suggests that prolonged latency and 
high amplitude of VEP may be associated with PD. 
In conclusion, our results met the aims of this study 
indicating that VEP results may be associated with 
severity of PD. Taking into the account of the results 
of the present study and those corroborating our 
results, VEP analysis can be suggested as a useful 
assessment in the diagnosis of visual problems in 
early PD. However, further work should be 
undertaken to establish whether VEP analysis can be 
effectively used in this regard. It is, thus, suggested 
that the effectiveness of VEP assessment in diagnosis 




1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. 
Stages in the development of Parkinson's disease-related pathology. 
Cell Tissue Res. 2004;318(1):121-34. 
2. Perfetti B, Moisello C, Lanzafame S, Varanese S, Landsness E, 
Onofrj M, Di Rocco A, Tononi G, Ghilardi MF. Attention 
modulation regulates both motor and non-motor performance: a 
high-density EEG study in Parkinson's disease. Archives italiennes 
de biologie. 2010;148(3):279-88. 
3. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, 
Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, 
Siderowf A, Tanner CM. Projected number of people with 
Parkinson disease in the most populous nations, 2005 through 2030. 
Neurology. 2007;68(5):384-6. 
4. Andalib S, Vafaee MS, Gjedde A. Parkinson's disease and 
mitochondrial gene variations: A review. J Neurol Sci. 2014. DOI: 
10.1016/j.jns.2014.07.067 (In Press) 
5. Jankovic J. Parkinson's disease: clinical features and diagnosis. 
J Neurol Neurosurg Psychiatry. 2008;79(4):368-76. 
6. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment 
of Parkinson disease: molecules to medicine. J Clin Invest. 
2006;116(7):1744-54. 
7. Farhoudi M, Sadigh-Eteghad S, Andalib S, Vafaee MS, Ziaee 
M, Mahmoudi J. An analytical review on probable anti-
parkinsonian effect of modafinil. J Analyt Res Clin Med. 
2013;1(2):58-62. 
8. Armstrong RA. Visual symptoms in Parkinson's disease. 
Parkinsons Dis. 2011;2011:908306. 
9. Bandini F, Pierantozzi M, Bodis-Wollner I. Parkinson's disease 
changes the balance of onset and offset visual responses: an evoked 
potential study. Clin Neurophysiol. 2001;112(6):976-983. 
10. Antal A, Terney D, Bodis-Wollner I. Parkinson's disease, aging, 
and visual cognition. Topics in Geriatric Rehabilitation. 
2008;24(2):166-81. 
11. Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. 
Visual hallucinations in Parkinson's disease: clues to separate origins. 
Journal of the neurological sciences. 2006;248(1):143-150. 
12. Okuda B, Tachibana H, Kawabata K, Takeda M, Sugita M. 
Visual evoked potentials (VEPs) in Parkinson's disease: correlation of 
pattern VEPs abnormality with dementia. Alzheimer Dis Assoc 
Disord. 1995;9(2):68-72. 
13. Gottlob I, Schneider E, Heider W, Skrandies W. Alteration of 
visual evoked potentials and electroretinograms in Parkinson's 
disease. Electroencephalogr Clin Neurophysiol. 1987;66(4):349-357. 
14. Yazdchi M, Talebi M, Aghbiglo AM, Mashrabi O. Role of visual 
evoked potential (VEP) and Somatosensory evoked potential (SSEP) 
in prediction Parkinson's diseases with dementia. Int J Curr Res Aca 
Rev.2(7):177-86. 
15. Gawel MJ, Das P, Vincent S, Rose FC. Visual and auditory 
evoked responses in patients with Parkinson's disease. J Neurol 
Neurosurg Psychiatry. 1981;44(3):227-32. 
16. Klistorner A, Garrick R, Barnett MH, Graham SL, Arvind H, 
Sriram P, Yiannikas C. Axonal loss in non-optic neuritis eyes of 
patients with multiple sclerosis linked to delayed visual evoked 
potential. Neurology. 2012;80(3):242-5. 
17. Talebi M, Sayadnasiri M, Azar SA. Effect of renal 
transplantation on visual evoked potential abnormalities of chronic 
renal failure. Transplant Proc. 2010;42(10):3994-7. 
18. Azar SA, Talebi M, Aghdam AT, Shishavan RH, Andalib S. 
Comparison of Visual Evoked Potentials in Patients Undergoing 
Peritoneal Dialysis and Hemodialysis and its Association with Blood 
Biochemical Profile. J Expand Clin Neuro. 2014;1(1). DOI: 
http://dx.doi.org/10.13183/jecns.v1i1.4 (In Press) 
19. Karlica D, Galetovic D, Ivanisevic M, Skrabic V, Znaor L, 
Jurisic D. Visual evoked potential can be used to detect a prediabetic 
form of diabetic retinopathy in patients with diabetes mellitus type I. 
Coll Antropol. 2010;34(2):525-9. 
20. Sener HO, Akbostanci MC, Yucesan C, Dora B, Selcuki D. 
Visual evoked potentials in Parkinson's disease-correlation with 
clinical involvement. Clin Neurol Neurosurg. 2001;103(3):147-50. 
21. Calzetti S, Franchi A, Taratufolo G, Groppi E. Simultaneous 
VEP and PERG investigations in early Parkinson's disease. Journal of 
Neurology, Neurosurgery & Psychiatry. 1990;53(2):114-7. 
22. Tartaglione A, Pizio N, Bino G, Spadavecchia L, Favale E. VEP 
changes in Parkinson's disease are stimulus dependent. Journal of 
Neurology, Neurosurgery & Psychiatry. 1984;47(3):305-7. 
23. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson 
disease. Archives of neurology. 1999;56(1):33-9. 
24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and 
mortality. 1967. Neurology. 2001;57(10 Suppl 3):S11-26. 
25. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, 
Association between Visual Evoked Potential and Disease Severity, Disease Duration…                                   Talebi et al. 
NBM 125 Novelty in Biomedicine 2014, 4, 120-5 
Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway 
R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt 
PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van 
Hilten JJ, LaPelle N. Movement Disorder Society-sponsored 
revision of the Unified Parkinson's Disease Rating Scale (MDS-
UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 
2007;22(1):41-7. 
26. Kurita A, Murakami M, Takagi S, Matsushima M, Suzuki M. 
Visual hallucinations and altered visual information processing in 
Parkinson disease and dementia with Lewy bodies. Movement 
Disorders. 2010;25(2):167-71. 
27. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, 
Kameyama M. The relation between visual hallucinations and visual 
evoked potential in Parkinson disease. Clin Neuropharmacol. 
2005;28(2):79-82. 
28. Onofrj M, Thomas A, D'Andreamatteo G, Iacono D, Luciano 
AL, Di Rollo A, Di Mascio R, Ballone E, Di Iorio A. Incidence of 
RBD and hallucination in patients affected by Parkinson's disease: 8-
year follow-up. Neurol Sci. 2002;23 Suppl 2:S91-4. 
29. Kupersmith MJ, Shakin E, Siegel IM, Lieberman A. Visual 
system abnormalities in patients with Parkinson's disease. Arch 
Neurol. 1982;39(5):284-6. 
 
 
 
 
 
 
